Information on this page is provided as a guide and may change. Please verify details directly with the treatment center or other appropriate source before making care decisions.

Institution Logo

Fox Chase Cancer Center Temple Health - Urologic Institute

Genitourinary Cancers Service Line

Primary Address

333 Cottman Ave
Philadelphia, PA, 19111
Appointment Scheduling Phone: (888) 369-2427
Program Website

Satellite Locations

Fox Chase Cancer Center at Buckingham

2365 Heritage Center Dr Furlong, PA 18925

Fox Chase Cancer Center at Chestnut Hill Hospital

8835 Germantown Ave Philadelphia, PA 19118

Fox Chase Cancer Center at East Norriton - Hospital Outpatient Center

2701 Dekalb Pike East Norriton, PA 19401

Fox Chase Cancer Center Vorhees

502 Centennial Blvd STE 7 Vorhees Township, NJ 08043

Fox Chase Cancer Center at Temple University Hospital

3509 N Broad St Philadelphia, PA 19140

Temple University Hospital - Jeanes Campis

7600 Central Ave Philadelphia, PA 19111

Temple Health at Fort Washington

515 Pennsylvania Ave Fort Washington, PA 19034

Volume

Metrics reflect this center’s demonstrated experience across key areas of kidney cancer care.

Kidney Cancer Surgery Volume

High

Clear Cell Kidney Cancer Diagnosis Volume

Medium

Non–Clear Cell Kidney Cancer Diagnosis Volume

Very High

Clinical Trial Participation Volume

Very High

Radiation & Ablation Procedure Volume

High

About these ratings

Volume and expertise levels are determined using standardized thresholds established by the Kidney Cancer Association and updated annually. Metrics are based on available data and may not reflect the full scope of a center’s capabilities or activity. These metrics are intended to help patients identify centers with demonstrated experience in kidney cancer care.

Types of Services Offered

Clinical Trials End of Life Services Genetic Counseling Infusion Center Integrative Oncology Molecular Testing Multidisciplinary Clinic Oncology Urgent Care Clinic Palliative & Supportive Care Patient Case Discussions / Tumor Boards Precision Medicine Survivorship Clinics Interventional Radiology Medical Oncology Pain Management Palliative Care Pathology Radiation Oncology Radiology Urologic Surgery

Kidney Cancer Types & Expertise

Chromophobe RCC Clear Cell RCC Collecting Duct RCC FH-deficient RCC Other Expertise Papillary RCC Renal Medullary Carcinoma Sarcomatoid Translocation RCC Tuberous Sclerosis–associated RCC Unclassified RCC VHL-associated RCC Bilateral Kidney Tumors Complex Recurrent Cases Cystic Renal Tumors Hereditary Syndromes Kidney Transplant Recipients Pediatric (diagnosed under age 18) Pregnancy Solitary Kidney Young Adult (age 18-50)

Other Expertise

Our kidney cancer team is a pioneer and internationally recognized leader in kidney-sparing surgery, minimally invasive surgery as a standard treatment option, and active surveillance of small kidney tumors.

Special Programs, Recognitions & Outcomes

American College of Surgeons Accredited Cancer Program Government-Funded Research NCI Designated Cancer Center Other

Research Programs

Clinical Multi-Institutional Collaboration Population-Based Research Lab Translational

Multi-Institutional Collaborations

Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC)
ECOG-ACRIN
NRG Oncology
SWOG Cancer Research Network

Patient Resources & Support Services

Art Therapy Fertility Preservation Counseling Financial Navigators Interpreter Services Lodging / Long-Term Housing Lymphedema Therapy Music Therapy Nurse Navigators Nutrition Services / Dietician Occupational Therapy On-site Dispensing / Pharmacy Parking Assistance (valet or concierge) Pastoral / Spiritual Care Patient Navigators Peer Support Options Physical Therapy Psychiatrists / Psychologists Social Workers / Counselors Transportation Service

Insurance Carriers

Accepted

  • Aetna
  • HMO
  • PPO
  • POS
  • Workers Comp
  • Aetna Medicare Advantage
  • Beech Street
  • Berkshire Health Partners
  • Coventry Medicare Advantage (falls under Aetna contract)
  • Cigna Health Plan (Commercial only)
  • Clover Health Plan (Medicare Advantage)
  • First Health Network (falls under Aetna contract)
  • Geisinger Health Plan
  • HMO
  • PPO
  • Medicare Advantage plans
  • Health Partners Plans
  • Medicaid
  • Medicare
  • Horizon Blue Cross Blue Shield of NJ
  • Commercial and Medicare Advantage plans
  • Workers Comp
  • Humana Medicare
  • Intergroup
  • Independence Blue Cross
  • Commercial
  • Medicare Advantage
  • Medicare Advantage Select 65
  • Comp Services (nonpar with Keystone 65 Focus)
  • Blue Cross Blue Shield Out of Area Plans (Highmark) can access TUHS via Blue Card (benefits must be verified)
  • Keystone First (Medicaid HMO)
  • Keystone VIP Choice Special Needs Plan
  • MultiPlan PPO plan
  • Optum Health Network
  • OSCAR Health (Commercial Exchange Plan)
  • PA Health and Wellness
  • Community Health Choices
  • Medicare
  • Prime Health Services
  • National Provider Network
  • Qualcare
  • United Healthcare Plan
  • HMO
  • PPO
  • United Healthcare Nursing Home Plan
  • VA Community Care Network
  • UPMC for Life (Community Health Choices)
  • UPMC For You (Health Choices)

Insurance information is provided as a guide and may change. Participation can vary by plan, location, and individual coverage. Please contact the treatment center and your insurance provider directly to confirm that your specific insurance plan is currently accepted and to understand any applicable coverage requirements or costs.

Open Clinical Trials

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

This phase III trial compares the effect of adding live biotherapy, MO-03, to standard of care (SOC) immunotherapy, including ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, and lenvatinib, to SOC immunotherapy alone in treating patients with clear cell renal cell cancer that may have spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started to other places in the body (metastatic). Studies have shown that gut health (the gut microbiome) may impact the effectiveness of immunotherapy. The microbiome includes all of the bacteria and organisms naturally found in the digestive tract. MO-03, a type of biotherapy, contains material from living organisms that may help keep the digestive tract healthy and may help to increase the effect of immunotherapy. Immunotherapy with monoclonal antibodies, such as ipilimumab, nivolumab, pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are a type of angiogenesis inhibitor and tyrosine kinase inhibitor (TKI) that block certain proteins which may help keep tumor cells from growing and may also help prevent the growth of new blood vessels that tumors need to grow. Adding MO-03 to SOC immunotherapy may be more effective than SOC immunotherapy alone in treating patients with advanced or metastatic clear cell renal cell cancer.
Request an Appointment